Frank Diehl is the Senior Vice President of Research & Development at Exact Sciences, where he leads efforts in cancer diagnostics. A recognized pioneer in liquid biopsy and circulating tumor DNA (ctDNA), he previously served as CEO of Sysmex Inostics and EVP at Thrive Earlier Detection. He earned his Ph. D. from Heidelberg University.
His postdoctoral research at Johns Hopkins Universitys Ludwig Center for Cancer Genetics and Therapeutics contributed to the development of the first noninvasive genetic screening test for cancer, Cologuard, which is now marketed by his current employer, Exact Sciences.